Yucheng Bio: Pioneering Chemiluminescent Urine-Specific Protein Testing and Expanding into Alzheimer's and Parkinson's Disease Diagnostics

Common technologies in immunodiagnostics primarily include chemiluminescence, colloidal gold, enzyme-linked immunosorbent assay (ELISA), and fluorescence immunoassay. Currently, the domestic immunodiagnostics industry in China is predominantly dominated by multinational in vitro diagnostics giants such as Roche, Abbott, Beckman (acquired by Danaher), and Siemens, which entered the market early and possess mature technologies.It currently monopolizes over 76% of the market share, while the market share of China's domestic industry is only 12%.。

Currently, the mainstream immunodiagnostic methods in China areChemiluminescence, with a market size exceeding 70% of the total immunoassay diagnostics market, but the domestic market is mainly monopolized by foreign giants such as Roche, Abbott, Beckman, and Siemens.Huge Potential for Domestic Substitution. According to a report by Frost & Sullivan, the compound annual growth rate (CAGR) of China’s immunodiagnostic market is projected to reach 21% from 2018 to 2023, with domestic companies achieving an overall growth rate (+24.1%) higher than that of foreign-funded enterprises (+19.3%).

Market expansion and the vast potential for domestic substitution do not necessarily benefit every player in the industry. As volume-based procurement advances, distributors face shrinking margins and intensifying competition, shifting the industry’s focus increasingly toward technology and manufacturing.Mr. Hu Yahui, CEO of Yucheng Biotech, drew on his 11 years of experience in the medical sales industry to make this assessment as early as the initial phase of centralized procurement in 2015.

Mr. Hu Yahui quickly led his team to conduct market research, collecting and analyzing information through extensive participation in trade shows, and leveraging his 11 years of sales experience in medical devices, he swiftly, the team decided to start with previously sold products—urinalysisWhat Hu Yahui valued at the time was the limited number of specialized manufacturers for urinalysis equipment, with significant gaps in quality control compared to large corporations such as Siemens. He ultimately chose urinary specific proteins as his entry point into the market.

Once the test target is determined, the next step is to select the testing platform. Chemiluminescence stands out due to its greater accessibility and broader potential.As a typical goal-driven individual, Hu Yahui quickly began to align the necessary talent and financial resources with the objectives of establishing chemiluminescence and urine-specific protein testing platforms.The first to join the team wasMs. Zhao, with 8 years of experience in R&D, production, and distribution management in the IVD industry, currently serving asVice President, Yucheng Biotechone position; technically, is a professional inHarvard Postdoctoral Fellow Who Earned the Title of Associate Professor at Age 30, he possesses exceptional academic expertise in neurodegenerative diseases, sleep disorders, and psychiatric conditions.Currently spearheading the R&D of specialty products for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at Yucheng Biotech.。

Driven by the joint efforts of the research team,Yucheng Biotech has currently launched five products, covering renal function, gastric function, infection, tumors, and Alzheimer’s syndrome and brain injury.。

Unlike most companies engaged in chemiluminescence, Shanghai Yucheng Biotech, while covering certain tumor detection assays,Renal function, Alzheimer’s disease (AD), and Parkinson’s disease (PD)—these three are their flagship products.. As one of the first companies in China to focus on urine-specific protein detection using chemiluminescence, Yucheng Biotech hasSix renal function tests have obtained Class II registration certificates in Shanghai.. While significantly reducing costs, its equipment monitoring data can also match the level of current large foreign-funded enterprises.

In the detection of AD and PD, Shanghai Yucheng Biotech has selected biomarkers that demonstrate significantly superior differential performance compared to traditional assays: P-tau217, Aβ1-42, AD7C-NTP, p-T181-tau, p-S396-tau, and S100.Rather than confining itself to the conventional role of a manufacturer, Hu Yahui led his team to aggressively expand upstream technical capabilities—starting with the establishment of an in-house raw materials laboratory and collaborations with research institutions for independent R&D—thereby enhancing the company’s strategic initiative within the industry chain.Over the nearly five years since its establishment, the company has consistently allocated a significant portion of its operating expenses to research and development each year.

If we are to explore the reasons behind Shanghai Yucheng Biotech’s steady progress in product coverage and technological mastery, it is because this is aMarket-Oriented Enterprise. Through 11 years of experience in selling diagnostic reagents, Hu Yahui has developed a comprehensive and nuanced understanding and judgment of the entire IVD market,Gain a thorough understanding of downstream demands, clearly identify clinical pain points, adopt product differentiation as the strategic framework, and pursue in-depth domain expertise as the development guideline., Yucheng Biotech is optimistic about the significant market share opportunities currently available to domestic IVD companies.

From Hu Yahui’s perspective, at a time when foreign giants monopolize the IVD market and there is substantial room for domestic substitution,Most domestic IVD companies in China are still at a stage of balanced competition in the market, and there is not yet a situation where a domestic IVD giant has replaced foreign enterprises and monopolized the market.. Therefore, for current domestically produced innovative IVD companies in China,Only by pursuing fundamental and effective innovation, upholding the spirit of craftsmanship in product quality control, and proactively fulfilling responsibilities in backend services can companies survive and lead in the future IVD market competition., which has also been the development posture pursued by Yucheng Biotech since its establishment.

“Current policies are highly favorable to biopharmaceutical manufacturers. If a national-level integrated platform is advanced, the days of distributors will be numbered,” said Hu Yahui in an interview.SHANGHAI YUCHENG BIOTECH CO.,LTD. has demonstrated absolute advantages in its transition from a distributor to a manufacturer, particularly in product differentiation, market familiarity, and product quality and service.

Yucheng Biotech is currently actively preparing for its multi-million-level financing round.In the future, Shanghai Yucheng Biotech is confident in achieving sales of RMB 45–50 million within two and a half years, reaching revenue break-even, while continuing to maintain its financial investment in research and development.

Yucheng Biotech, established with the shareholders’ own capital, has opted against the fast track to profitability. Instead, it has strategically targeted market opportunities, dedicating itself to deep cultivation of non-mainstream sectors in pursuit of meaningful innovation and high-quality products.The more such enterprises, the better!